On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
A year after kicking off a star-studded campaign to highlight the stories of real patients with atopic dermatitis, Incyte has ...
Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...
All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...
Earlier this year, Evonik unveiled a restructuring project that will result in up to 2,000 layoffs. | After Evonik in March ...
In less than a month, Americans will head to the polls—or vote by mail—and elect the next president of the U.S. | While a ...
In this interview, recorded live at Digital Pharma East, Kamya Elawadhi – Chief Client Officer at Doceree – discusses the ...
By enhancing patients’ understanding, skills, and confidence, the company is revolutionizing the way healthcare content is ...
By Lalit Saxena, Senior Director of MSAT, and Sungkeum Seo, Director of MSAT Labs Upstream Processing at Samsung ...
When it comes to pharma marketing in 2024, there is perhaps no bigger discussion than privacy. | When it comes to pharma marketing in 2024, there is perhaps no bigger discussion than privacy. From new ...
Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Pharma East.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback